July was a blockbuster month for China’s biotech scene. AstraZeneca alone inked three mega‑partnerships—an inhaled PDE3/4 inhibitor with Chia Tai Tianqing ($2.1 bn), a siRNA platform and two kidney‑target drugs with CSPC Pharmaceutical ($1.77 bn), and a novel therapy with Dizal Pharma ($1.5 bn)—totaling more than $5.3 billion. The deals underline how eager global drug makers are to tap China’s innovative pipelines. Chinese firms are also stepping up. CSPC’s AI‑driven siRNA platform moved into commercialisation, while Hansoh licensed an oral IL‑23 antagonist to Avere Therapeutics, pocketing a $120 million upfront payment and up to $2.18 billion in milestones. On the R&D front, the country approved five new medicines—including a psoriasis antibody and a novel insulin—while eight products filed fresh NDAs covering cancers, vaccines and metabolic disorders. Twelve projects entered Phase III trials, ranging from RSV vaccines to ovarian‑cancer antibody‑drug conjugates. Analysts say the surge in licensing, approvals and late‑stage trials signals a maturing ecosystem. With mid‑year earnings reports from heavy‑hitters like BeiGene and Innovent on the horizon, investors expect the momentum to translate into stronger financial performance for China’s innovative‑drug sector.
Read more